# Payers as gatekeepers: how insurers and health systems decide what actually sells
In 2015, Gilead's hepatitis C cure Sovaldi hit US pharmacies with a list price of $84,000 for a 12 week course. The drug was clinically extraordinary: cure rates above 90%. But insurers panicked, state Medicaid programs (US government health coverage for low income residents) rationed it to only the sickest patients, and it took years of formulary fights before access broadened. The lesson stuck with the whole industry: a great drug means nothing if the people who pay for it say no.
That's the subject of this lesson. Payers, not regulators, are often the real gatekeepers of commercial success.
A payer is whoever actually foots the bill for a medicine, distinct from the patient who takes it and the regulator who approves it.
Regulators like the FDA (US Food and Drug Administration) or EMA (European Medicines Agency) answer one question: is this drug safe and effective enough to sell at all? Payers answer a different, often harsher question: is it worth what you're charging?
In the US, insurers and their PBMs (pharmacy benefit managers, companies like CVS Caremark, Express Scripts, and OptumRx that negotiate drug prices and manage formularies on behalf of insurers) build a "formulary": a tiered list of which drugs are covered, at what patient cost, and under what restrictions.
Manufacturers compete for favorable formulary placement much like consumer brands compete for supermarket shelf space. Mechanics include:
This creates real competitive leverage. Three PBMs control an estimated 70 to 80% of US prescription volume (estimate, widely cited in industry and congressional analyses as of the mid-2020s). That concentration gives them significant pricing power over manufacturers, even ones with blockbuster drugs.
The UK takes a more transparent, centralized approach. NICE evaluates new drugs using a standardized metric: the QALY (quality-adjusted life year, a measure combining length and quality of life gained from treatment).
NICE's long-standing willingness-to-pay threshold has generally sat around £20,000 to £30,000 per QALY gained (published NICE methodology, figures can shift for specific disease areas such as end-of-life cancer treatments). If a drug's cost per QALY comes in above that range, NICE can simply say no, regardless of how well it works clinically.
Simple worked example:
Suppose Drug X costs £15,000 per patient per year and extends life by 1.5 quality-adjusted years compared to standard care.
Cost per QALY = £15,000 ÷ 1.5 = £10,000 per QALY
That comfortably clears NICE's threshold zone, likely leading to approval for NHS funding. Now suppose the same drug costs £60,000 per year for the same 1.5 QALY gain:
£60,000 ÷ 1.5 = £40,000 per QALY
That's above the typical threshold, putting NHS funding at real risk unless the manufacturer offers a confidential discount (common in practice) or the disease qualifies for a higher threshold exception.
This is why manufacturers frequently launch in the UK at a discount, or negotiate confidential "patient access schemes," to get under the line. NICE's rulings also ripple globally: many countries reference UK, German, or other advanced-market prices when setting their own, a practice called international reference pricing.
For a primer on how these evaluations actually work, NICE publishes its own accessible methodology guide: NICE guide to health technology evaluation.
Payers reshape competitive dynamics in ways clinical trial data alone never could:
1. Second-to-market drugs can still win. If a "me-too" drug (a similar molecule targeting the same condition as an existing one) offers a modest efficacy edge but a much better cost-per-QALY or accepts a steeper rebate, it can out-compete a clinically superior rival for formulary placement.
2. Payer power varies by disease area. In rare diseases with no alternative treatment, payers have less leverage. In crowded categories, like diabetes or cholesterol drugs, payers can play manufacturers off each other for rebates.
3. Health system structure shapes launch strategy. Companies often sequence launches: pricing high in the less price-sensitive US market first, then negotiating down for UK, German, or other reference-pricing markets later.
4. Value-based contracts are emerging. Some payers now tie reimbursement to real-world outcomes: pay less if the drug underperforms in practice. This shifts commercial risk back onto manufacturers.
Vérification des acquis
1. What core distinction does the Sovaldi hepatitis C example illustrate about drug commercialization?
2. How does the fundamental question a payer asks differ from the question a regulator asks?
3. A company is planning market access strategy for a new drug in a country with a single dominant public payer (like the UK's NHS advised by NICE). What is the key strategic implication compared to the fragmented US payer landscape?
4. Select ALL correct answers about who functions as a 'payer' in a given health system.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers describing why payers are described as 'gatekeepers' of commercial success in the pharmaceutical industry.
Sélectionnez toutes les réponses correctes.
It helps to rank leverage across the chain:
This is why pharma executives increasingly say "payers are the new regulators." A drug can sail through FDA approval and still commercially fail if PBMs won't place it favorably or NICE rejects its price.